title: Eurotransplant. Part II. The cyclosporine era 1981-1985.
abstract: 1. The realization of the two main goals of the Eurotransplant Organization have been enhanced during the period between 1981 and 1985 by two factors: A reliable HLA-A, -B and -DR typing of kidney donors and recipients, reflected in this analysis by the Hardy-Weinberg analysis but also by the results of the regular tissue typing quality controls. The number of patients who received a kidney without HLA-DR mismatches was 53% (N = 2,904). A significant difference with the 390 of 5,535 (7%) patients who received a kidney with two HLA-DR mismatches. 2. Treatment with cyclosporine increases kidney graft survival significantly in recipients of a first cadaveric transplant which is in agreement with the results of many other groups. Also a significant improvement in kidney graft survival with cyclosporine treatment was observed in recipients of a cadaveric retransplant, an observation in contrast with those of UCLA. 3. Although no significant influence of HLA-A and -B matching was observed in patients treated with or without cyclosporine, the best matched patients had the best graft survival. As stated many times before, the beneficial effect of HLA-A and -B matching is best demonstrated four or five years posttransplantation. 4. The effect of HLA-DR matching on kidney graft survival is highly significant, regardless of whether cyclosporine has been used or not. This finding is also in accordance with those of other investigators. 5. Prolonged cold ischemia periods in cyclosporine-treated patients resulted in a significant decrease of kidney graft survival. This is in contrast with the observations in non-cyclosporine-treated recipients.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: G G
authors.initials: GG
authors.lastname: Persijn
authors.forename: P
authors.initials: P
authors.lastname: de Lange
authors.forename: J
authors.initials: J
authors.lastname: D'Amaro
authors.forename: B
authors.initials: B
authors.lastname: Cohen
authors.forename: P
authors.initials: P
authors.lastname: Liebelt
authors.forename: G F
authors.initials: GF
authors.lastname: Hendriks
authors.forename: J J
authors.initials: JJ
authors.lastname: van Rood
mesh_terms: D003524:Cyclosporins / Q000627:therapeutic use*; D005060:Europe; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology* / Q000706:statistics & numerical data; D012955:Societies, Medical
chemical_list: D003524:Cyclosporins